Peptides for Hair Growth: Which Ones Have Evidence and Which Are Marketing

Search peptides for hair growth and you get two kinds of page: a listicle of ten compounds with no evidence attached to any of them, and a cosmetics brand explaining that its shampoo contains a peptide complex, without naming the peptide. Neither answers the real question, which is whether any of this moves a hair count.

This page grades the field: where the follicle cycle lets a peptide act, the compounds with real published work behind them, the ones that are marketing, why topical and injected routes answer different questions, and what a realistic timeline looks like. The androgenetic alopecia side, meaning DHT, finasteride and how peptides sit alongside the treatments that do have large trials, is on the peptides for hair loss page, and the copper peptides have their own page at copper peptides for hair. Everything below is research use information: none of these compounds is an approved treatment for hair loss, and nothing here is medical advice.

How Hair Growth Works, and Where a Peptide Could Act

A scalp carries roughly 100,000 follicles, each cycling independently of its neighbours, which is why hair does not fall out in sheets. At any moment 85 to 90 percent are in anagen, the growth phase, and 10 to 15 percent are resting, and that ratio is what every hair intervention is trying to shift.

Pattern loss is not one of the phases. It is a drift: each successive anagen runs shorter, the follicle builds a thinner shaft, and over years a terminal hair becomes a vellus one. That is miniaturisation, and it is what both the count question and the thickness question come down to. A peptide can reach this system in four ways that have published support, none of which touches the androgen driving the drift.

• Growth factor signalling. The dermal papilla talks to the follicle through VEGF, which builds the capillary loop that feeds it, and through KGF and FGF. Compounds that raise these aim at follicle size.
• Wnt and beta-catenin. This pathway decides whether a follicle enters anagen at all, it is suppressed in balding scalp, and reactivating it is the most direct route to a longer growth phase.
• Stem cell activation. The bulge holds quiescent follicle stem cells and wound healing signals wake them, which is why microneedling does something on its own.
• Inflammation. Perifollicular inflammation is visible on biopsy around miniaturising follicles. It regrows nothing to reduce it, but it improves the environment the other three work in.

The Compounds With Actual Evidence

Evidence here means a published experiment with a hair endpoint, not a mechanism that could plausibly affect hair. By that standard the field is small, and the grading is uncomfortable, because the compound with the best research record is not the one with the best hair record.

GHK-Cu, the copper peptide everyone means

GHK is a tripeptide identified in 1973 in human albumin, and it binds copper at an affinity close to albumin's own transport site (Pickart et al., Oxid Med Cell Longev 2012, PMID 22666519). Its plasma level falls with age (Pickart et al., Biomed Res Int 2015, PMID 26236730), it raises VEGF, KGF and FGF-2 in culture, and it has a randomised controlled trial behind it in diabetic foot ulcers, where a GHK-Cu gel reached a median 98.5 percent closure against 60.8 percent for vehicle (Mulder et al., Wound Repair Regen 1994, PMID 17147644); the GHK-Cu guide has the rest of that record. What it does not have is a hair study, in any species, and the two preclinical papers usually cited for its hair effect tested something else.

AHK-Cu, the copper peptide the follicle work actually used

Pyo and colleagues showed that a copper tripeptide stimulated elongation of human hair follicles cultured outside the body and made dermal papilla cells proliferate, at picomolar to nanomolar concentrations (Arch Pharm Res 2007, PMID 17703734). The peptide was AHK-Cu, alanyl-histidyl-lysine copper, a relative of GHK-Cu and not the same molecule. This is the most direct hair evidence for any copper peptide, and it is why AHK-Cu turns up next to GHK-Cu in scalp serums. The copper peptides for hair page takes the two apart.

PC1031, the coded copper peptide in rats

Uno and Kurata reported that a copper binding peptide identified only by the code PC1031 enlarged follicles on the back skin of fuzzy rats, with an effect they compared to topical minoxidil (J Invest Dermatol 1993, PMID 8326148). The abstract does not identify PC1031 as GHK-Cu. This paper is cited constantly as proof that copper peptides grow hair, and the citation usually misstates which peptide it was.

PTD-DBM and the Wnt pathway

The 2017 Journal of Investigative Dermatology work on CXXC5 is the mechanistically cleanest hair result in the peptide literature. CXXC5 binds dishevelled and suppresses Wnt signalling, it accumulates in balding scalp, and a competing peptide called PTD-DBM displaces it and reactivates the pathway; hair regrew in mice and in cultured human follicles. Its protein transduction domain gets it across a cell membrane, so it suits topical delivery better than most peptides its size. The catch is supply: verified PTD-DBM is expensive and few vendors carry it with a credible certificate of analysis. Protocols using it are on the hair loss page.

Thymosin beta-4 and TB-500

Thymosin beta-4 is a 43 amino acid wound healing protein, and mouse work in the 2000s reported that it accelerated hair growth and activated quiescent follicle stem cells through VEGF and progenitor cell migration. That is a real hair endpoint, in mice, for the full protein. TB-500, which is what research vendors sell, is a synthetic fragment of it, and no hair study used the fragment; the TB-500 guide covers a distinction that undermines most claims made about the two names interchangeably. In scalp protocols it appears as an injected component, because at that size passive skin penetration is not realistic.

KPV and zinc thymulin

KPV is the C-terminal tripeptide of alpha-MSH, an anti-inflammatory rather than a growth signal, so it belongs in the fourth category above: useful where inflammation is the visible problem, with no hair specific study behind it. Zinc thymulin is weaker still. It appears in hair marketing on the strength of a small pilot circulated around 2016, and we could not locate an indexed, peer reviewed trial of it for hair growth on PubMed in September 2026.

The Ones That Are Marketing

Collagen peptides

This is the biggest source of confusion in the category, because the word peptide is doing two jobs. A signalling peptide is a short sequence a receptor or pathway recognises as a message. Collagen peptides are hydrolysed collagen protein taken by mouth in scoops, and digestion reduces most of it to free amino acids and small di and tripeptides that enter the general amino acid pool. Hair is keratin: it is not made of collagen. The supportive studies are small, usually funded by the ingredient supplier, and score self reported hair quality rather than a counted density. If protein intake is genuinely low, adding protein helps hair along with everything else, but that is nutrition, not what GHK-Cu or PTD-DBM are doing.

Peptide complexes with no named peptide

A label saying peptide complex or growth factor blend, without an ingredient name you can look up, is telling you nothing. Copper Tripeptide-1 is a name you can check; a trade name for a mixture is not. The topical GHK-Cu page covers how to read one of these labels, including where in the list the peptide has to sit before it is present in any useful amount.

Peptide shampoos and oral capsules

A shampoo sits on the scalp for about ninety seconds and is then rinsed off. A leave-on serum already struggles with penetration; a rinse-off product built around surfactants is not a delivery system, and where a shampoo helps it is the ketoconazole or zinc pyrithione doing it. Capsules have the opposite problem: a tripeptide swallowed meets the same proteases as any dietary protein, and nothing published shows intact GHK-Cu surviving digestion and reaching a follicle.

Topical Against Injected, for a Target Three Millimetres Down

A terminal anagen follicle sits two to four millimetres below the surface, and that one fact decides the route argument. The target is not far away, but the stratum corneum stands between a scalp solution and it, and most of these peptides are hydrophilic and charged, which is the wrong profile for crossing a lipid barrier. GHK-Cu weighs about 404 daltons, under the 500 dalton rule of thumb for passive diffusion, and copper peptide complexes have been shown to cross a model membrane built from stratum corneum lipids in a Franz cell (Mazurowska and Mojski, J Cosmet Sci 2008, PMID 18350235). That establishes that penetration is possible, not how much.

Two things follow. Concentration is the wrong lever, because fibroblasts respond to GHK-Cu from about a picomolar, peaking near one nanomolar (Maquart et al., FEBS Lett 1988, PMID 3169264), while a 0.1 percent scalp tonic is millions of times that. And anything that disrupts the barrier matters more than anything that raises the percentage, which is why microneedling is paired with topical hair peptides so consistently.

Injection appears in two forms. Intradermal scalp mesotherapy, a grid of small injections done in a clinic, bypasses the barrier entirely, and it is where the only human report of injected copper peptide for hair comes from: an uncontrolled, open label series of 1,000 patients treated with a six component growth factor cocktail containing copper tripeptide-1 (Kapoor and Shome, J Cosmet Laser Ther 2018, PMID 29482481). It reported the treatment as well tolerated and says nothing about any single ingredient. Subcutaneous injection is the other, and it is a systemic dose aimed at a local target. The copper peptides page sets out the amounts in circulation for both.

What a Realistic Timeline Looks Like

The follicle sets the pace and no compound here changes that. Hair grows about a centimetre a month, telogen lasts about three months, and a follicle pushed back into anagen still has to build a shaft, so the earliest honest read is three months and the real read is six to twelve.

Shedding in the first six to eight weeks is common whenever something changes the cycle, and it is the most frequent reason people quit a protocol that has not yet had a chance to fail: when a telogen follicle restarts, the new shaft pushes the old club hair out. Thickness moves on its own schedule, because shaft diameter is set by follicle size and anagen length, which is why perceived density can improve while a hair count barely moves.

How to Think About Stacking

The full topical protocol people build from these compounds, with concentrations and a microneedling schedule, is on the peptides for hair loss page. The stacks that make sense follow three rules.

One mechanism each. Three compounds that all raise growth factors is one mechanism bought three times; the combinations that appear in practice pair a growth factor compound with a Wnt compound and, where inflammation is visible, an anti-inflammatory. Solve delivery before adding compounds. If very little of the solution reaches the dermis, a fourth peptide changes nothing and microneedling changes everything. The established treatments are the floor, not the competition. Minoxidil and the DHT blockers have the trial evidence these compounds do not, and they cover mechanisms peptides do not, so for most people peptides are an addition to that foundation rather than a replacement for it.

Key Takeaways

• The follicle cycle, not the compound, sets the timeline: three months for a baseline photograph, six to twelve for an answer
• AHK-Cu has the most direct hair data of any peptide, and it is not GHK-Cu
• There is no published human trial of any of these compounds for hair growth
• PTD-DBM has the cleanest mechanism and the worst supply situation
• Vendors sell TB-500, a fragment; the hair work used full length thymosin beta-4
• Delivery beats concentration. A label percentage is a statement of intent, not of potency at the follicle
• Collagen peptides are protein, not a signal, and hair is keratin rather than collagen
• A shed at week six is the expected consequence of a cycle shift, not evidence that the protocol failed
• Every page claiming the rat study proves GHK-Cu grows hair is citing a peptide the abstract calls PC1031

Frequently Asked Questions

What peptides actually grow hair?

Four have published work with a hair endpoint. AHK-Cu lengthened human hair follicles in culture and made dermal papilla cells proliferate. A copper peptide coded PC1031 enlarged follicles in rats, with an effect the authors compared to topical minoxidil. PTD-DBM reactivated Wnt signalling by blocking CXXC5 and regrew hair in mice. Thymosin beta-4 woke quiescent follicle stem cells in mice. None has a randomised human trial for hair, and GHK-Cu, the copper peptide most people mean, has no hair study of its own in any species.

What is the best peptide for hair growth and thickness?

On published evidence the copper peptides are ahead: AHK-Cu has the direct follicle data, and GHK-Cu is the one that is actually available. Thickness is a separate measurement from count, because shaft diameter is set by follicle size and anagen length, which is why the copper peptide work on follicle enlargement is the part of the literature that bears on it. Nothing here has been measured against finasteride or minoxidil head to head, so best means best evidenced within a weakly evidenced field.

Do collagen peptides help hair growth?

Collagen peptides are hydrolysed protein taken by mouth, not signalling peptides in the sense this page uses. Digestion reduces most of the material to amino acids and small di and tripeptides that enter the general amino acid pool rather than arriving at a follicle as a message, and hair is keratin rather than collagen. The supportive studies are small, mostly industry funded, and score self reported hair quality rather than counted hairs. If protein intake is low, more protein can help hair, but that is nutrition, not a peptide effect.

How long do peptides take to work for hair?

The follicle sets the pace, not the compound. Scalp hair grows roughly a centimetre a month, telogen lasts about three months, and a follicle pushed back into growth still has to build a visible shaft, so the earliest honest read is three months and the real read is six to twelve. Shedding in the first six to eight weeks is common when anything changes the cycle and is not by itself a failure signal.

Are hair growth peptides topical or injected?

Mostly topical, because the target sits two to four millimetres down in the dermis and a scalp solution only has to cross the stratum corneum to reach it. Copper peptides, PTD-DBM and KPV are used this way. Injection appears as intradermal scalp mesotherapy in clinics, which is where the only human report of injected copper peptide for hair comes from, and as subcutaneous systemic injection, a whole body dose aimed at a local target. Microneedling is paired with topicals so often because the penetration barrier is the limiting factor.